21 March 2024 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival Download Presentation Webcast Workbook
7 March 2024 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial Download Presentation Webcast Workbook
22 February 2024 Invitation to Scandion Oncology webcast and conference call February 28, 2024 Download Presentation Webcast Workbook
31 January 2024 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial Download Presentation Webcast Workbook
5 January 2024 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 Download Presentation Webcast Workbook
21 December 2023 CORIST part 3 topline data are expected in the second half of January 2024 Download Presentation Webcast Workbook
15 December 2023 Scandion Oncology identifies potentially effective treatment of gastric cancer Download Presentation Webcast Workbook
29 November 2023 Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 Download Presentation Webcast Workbook
21 November 2023 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months Download Presentation Webcast Workbook
15 November 2023 Invitation to Scandion Oncology webcast and conference call November 22, 2023 Download Presentation Webcast Workbook
16 October 2023 Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data. Download Presentation Webcast Workbook
12 September 2023 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer Download Presentation Webcast Workbook